Want to see TSE:MDNA full AI Analyst Report?
MDNA Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MDNA Stock 12 Month Forecast
Average Price Target
C$1.60
▲(86.05% Upside)
| Highest Price TargetC$1.60 | Average Price TargetC$1.60 | Lowest Price TargetC$1.60 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Research Capital
C$3.75→C$1.6
Buy
86.05%
Upside
Reiterated
06/29/26
Why this analyst just chopped his price target on Medicenna TherapeuticsResearch Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) has upcoming clinical catalysts, but he has lowered his target after removing MDNA55 partnership assumptions from his valuation.
Bloom Burton
C$4
Buy
365.12%
Upside
Reiterated
12/11/25
We have also adjusted our assumption for a $50M near term equity issuance at $2.00 to $1.10. The mixed data at ESMO-IO and resulting adjustments to our model have reduced our target price to C$4.00* (previously US$6.00). Nevertheless, MDNA stock remains a BUY (Speculative) as we continue to believe that MDNA11 is active. The company held $15.7M at September 30, burning approximately $5M/quarter.
Lucid Capital
C$4
Buy
365.12%
Upside
Initiated
10/14/25
H.C. Wainwright
C$3.54
Buy
311.40%
Upside
Reiterated
08/04/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Research Capital
C$3.75→C$1.6
Buy
86.05%
Upside
Reiterated
06/29/26
Why this analyst just chopped his price target on Medicenna TherapeuticsResearch Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) has upcoming clinical catalysts, but he has lowered his target after removing MDNA55 partnership assumptions from his valuation.
Bloom Burton
C$4
Buy
365.12%
Upside
Reiterated
12/11/25
We have also adjusted our assumption for a $50M near term equity issuance at $2.00 to $1.10. The mixed data at ESMO-IO and resulting adjustments to our model have reduced our target price to C$4.00* (previously US$6.00). Nevertheless, MDNA stock remains a BUY (Speculative) as we continue to believe that MDNA11 is active. The company held $15.7M at September 30, burning approximately $5M/quarter.
Lucid Capital
C$4
Buy
365.12%
Upside
Initiated
10/14/25
H.C. Wainwright
C$3.54
Buy
311.40%
Upside
Reiterated
08/04/25
Best Analysts Covering Medicenna Therapeutics Corp
3 Months
Success Rate
5/9 ratings generated profit
Average Return
+50.59%
Copying Andre Uddin's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +50.59% per trade.
1 Year
Success Rate
6/9 ratings generated profit
Average Return
+178.40%
Copying Andre Uddin's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +178.40% per trade.
2 Years
Success Rate
4/9 ratings generated profit
Average Return
+79.40%
Copying Andre Uddin's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +79.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MDNA Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
1
1
Buy
0
0
0
0
0
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
1
1
2
1
Each month's total comprises the sum of three months' worth of ratings.
MDNA Financial Forecast
MDNA Stock Forecast FAQ
What is TSE:MDNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Medicenna Therapeutics Corp’s 12-month average price target is 1.60.
What is TSE:MDNA’s upside potential, based on the analysts’ average price target?
Medicenna Therapeutics Corp has 86.05% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TSE:MDNA a Buy, Sell or Hold?
Medicenna Therapeutics Corp has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Medicenna Therapeutics Corp’s price target?
The average price target for Medicenna Therapeutics Corp is 1.60. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is C$1.60 ,the lowest forecast is C$1.60. The average price target represents 86.05% Increase from the current price of C$0.86.
The highest analyst price target is C$1.60 ,the lowest forecast is C$1.60. The average price target represents 86.05% Increase from the current price of C$0.86.
What do analysts say about Medicenna Therapeutics Corp?
Medicenna Therapeutics Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of TSE:MDNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.